Hunton Andrews Kurth Continues Global Energy Team Expansion in London
11.12.2024 10:00:00 CET | Business Wire | Press release
One Year of Sustained Local Growth Includes More Than Two Dozen Lawyers
Hunton Andrews Kurth LLP continues to expand in London with the addition of nearly a dozen highly regarded energy and project finance lawyers.
Partners Charles Morrison, Dimitri Papaefstratiou, Simon Collier, Harry Brunt, Counsel Joseph Lam, and ConsultantGrant Henderson, along with five associates, have joined the firm from Ernst & Young’s legal services arm, EY Law. The team focuses on transactions in various energy sectors, such as oil and gas, renewable and thermal power, as well as emerging technologies of carbon capture, hydrogen and energy storage.
“The addition of these distinguished lawyers underscores our commitment to maintaining our position as a leading adviser to the global energy industry,” said Hunton Andrews Kurth Managing Partner Sam Danon. “The team aligns well with our international growth strategy, which is focused on ensuring that we’ve achieved critical mass in key practices, in core industry focus areas and in geographies where client demand is strong.”
“Energy sector activity remains incredibly robust, driven by the need for renewable and alternative solutions in support of the energy transition as well as the need for infrastructure and traditional resource development in emerging and mature economies,” added Jeff Schroeder, head of Hunton Andrews Kurth’s energy and infrastructure team. “We are particularly excited about the team’s capabilities to grow the pipeline of complex, cross-border energy projects and adding depth to our global energy practice.”
In support of its international growth strategy, since August 2023, Hunton Andrews Kurth has added more than two dozen lawyers to its London office. Most recently, finance Partners Alan Cunningham and Richard Skipper joined the firm from EY Law. In September, the firm added project finance Partners Ayesha Waheed and Seyfi Can Kandemir. Last year, Hunton Andrews Kurth welcomed to Londoncorporate energy Partner Philip Mace and energy and infrastructure disputes Partners Maurice Kentonand David Hesse, Counsel Edward Hamiltonand Special Counsel Simon Schooling, who collectively are leading members of the firm’s international arbitration team.
“Our energy-focused corporate and disputes teams in London have experienced tremendous growth over the past year, expanding our reach throughout Europe, the Middle East and Africa,” said Ferdinand Calice, managing partner of Hunton Andrews Kurth’s London office. “We are pleased to welcome our newest colleagues to the firm.”
About Hunton Andrews Kurth’s Energy and Infrastructure Team
Hunton Andrews Kurth’s global energy and infrastructure lawyers assist clients in bringing some of the world’s largest and most complex projects to market. Our team provides concept-to-close advice on the development and financing of capital-intensive projects. We represent sponsors, lenders, investors, governments, and other project participants operating in virtually every segment of the energy industry and infrastructure industry. Our projects attorneys have handled transactions in more than 75 countries, with market leading strengths in project finance, agency finance, commercial nuclear power, U.S. energy tax credits, subsea fiber-optic networks, and utility capital markets, among many others.
About Hunton Andrews Kurth LLP
For more than 120 years, Hunton Andrews Kurth has served clients across the globe with a collaborative and purposeful approach. With offices strategically located in the United States and around the world, the firm is known for its strength in the energy, financial services, real estate, and retail and consumer products industries, as well as its considerable depth across numerous practice areas. Hunton Andrews Kurth fosters a strong culture built upon an unwavering commitment to its clients, colleagues, and communities. To learn more, please visit huntonak.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211423314/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom